This experience strongly reinforces the guideline recommendation for prompt gBRCA1/2 testing in all patients with HER2− advanced breast cancer at diagnosis, because earlier identification could optimize treatment sequencing. This evidence concerns the gene ERBB2 and breast carcinoma.